InvestorsHub Logo
Followers 16
Posts 484
Boards Moderated 0
Alias Born 11/10/2013

Re: None

Friday, 07/10/2020 9:10:39 AM

Friday, July 10, 2020 9:10:39 AM

Post# of 185
STIFEL NICOLAUS MAINTAINS THEIR BUY RATING ON PHASEBIO PHARMACEUTICALS (PHAS)

July 10, 2020

https://www.markets.co/stifel-nicolaus-maintains-their-buy-rating-on-phasebio-pharmaceuticals-phas/260723/?ref=tipranks


Stifel Nicolaus analyst Derek Archila maintained a Buy rating on Phasebio Pharmaceuticals (PHAS – Research Report) today and set a price target of $11.00. The company’s shares closed last Thursday at $4.57.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 5.4% and a 46.2% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Phasebio Pharmaceuticals is a Strong Buy with an average price target of $14.75.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PHASQ News